4-{[1-(6-cyanopyridazin-3-yl)piperidin-4-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide | 1039739-63-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 4-{[1-(6-cyanopyridazin-3-yl)piperidin-4-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide
• 英文别名: 4-[[1-(6-cyanopyridazin-3-yl)piperidin-4-yl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide
• CAS: 1039739-63-3
• 化学式: C₁₈H₁₈N₈O
• 分子量: 362.394
• InChiKey: WEAYOCOHYLCUOF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  137
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  4-氯-1H-吡咯并[2,3-B]吡啶-5-羧酰胺 在 1,3-二甲基-2-咪唑啉酮 、 盐酸 、 三乙胺 作用下， 以 1,4-二氧六环 、 N-甲基吡咯烷酮 、 乙醇 为溶剂， 反应 2.5h， 生成 4-{[1-(6-cyanopyridazin-3-yl)piperidin-4-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide
  参考文献：
  名称：

  Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3

  摘要：

  Janus kinases (JAKs) regulate various inflammatory and immune responses and are targets for the treatment of inflammatory and immune diseases. As a novel class of immunomodulators targeting JAK3, 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives are promising candidates for treating such diseases. In chemical modification of lead compound 2, the substitution of a cycloalkyl ring for an N-cyanopy-ridylpiperidine in C4-position was effective for increasing JAK3 inhibitory activity. In addition, modulation of physical properties such as molecular lipophilicity and basicity was important for reducing human ether-a-go-go-related gene (hERG) inhibitory activity. Our optimization study gave compound 31, which exhibited potent JAK3 inhibitory activity as well as weak hERG inhibitory activity. In cellular assay, 31 exhibited potent immunomodulating effect on IL-2-stimulated T cell proliferation. In a pharmacokinetic study, good metabolic stability and oral bioavailability of 31 were achieved in rats, dogs, and monkeys. Further, 31 prolonged graft survival in an in vivo rat heterotopic cardiac transplant model. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.05.034

文献信息

• CONDENSED PYRIDINE COMPOUND
  申请人：Shirakami Shohei

  公开号：US20100105661A1

  公开（公告）日：2010-04-29

  The present invention provides a compound having excellent JAK3 inhibitory activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases, inflammatory diseases, and allergic diseases. As a result of investigations with respect to novel condensed heterocyclic derivatives, the inventors have verified that a condensed pyridine compound has excellent JAK3 inhibitory activity, thereby completing the present invention. More specifically, it has been verified that since the compound according to the present invention has inhibitory activity against JAK3, the compound is useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transduction (e.g., rejection during live organ/tissue transplantation, autoimmune diseases, asthma, atopic dermatitis, rheumatism, psoriasis and atherosclerotic disease), or diseases caused by abnormal cytokine signal transduction (e.g., cancer and leukemia).

  本发明提供了一种具有出色JAK3抑制活性的化合物，可作为治疗和/或预防各种免疫疾病，包括自身免疫性疾病、炎症性疾病和过敏性疾病的药剂的有效成分。通过对新型紧缩杂环衍生物的研究，发明人已经验证，紧缩吡啶化合物具有出色的JAK3抑制活性，从而完成了本发明。更具体地说，已经验证，由于本发明的化合物具有对JAK3的抑制活性，因此该化合物可用作治疗或预防由不良细胞因子信号转导引起的疾病（例如，在活体器官/组织移植期间的排斥反应、自身免疫性疾病、哮喘、特应性皮炎、风湿病、牛皮癣和动脉粥样硬化疾病），或由异常细胞因子信号转导引起的疾病（例如癌症和白血病）的有效成分。
• Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3
  作者：Yutaka Nakajima、Takayuki Inoue、Kazuo Nakai、Koichiro Mukoyoshi、Hisao Hamaguchi、Keiko Hatanaka、Hiroshi Sasaki、Akira Tanaka、Fumie Takahashi、Shigeki Kunikawa、Hiroyuki Usuda、Ayako Moritomo、Yasuyuki Higashi、Masamichi Inami、Shohei Shirakami

  DOI：10.1016/j.bmc.2015.05.034

  日期：2015.8

  Janus kinases (JAKs) regulate various inflammatory and immune responses and are targets for the treatment of inflammatory and immune diseases. As a novel class of immunomodulators targeting JAK3, 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives are promising candidates for treating such diseases. In chemical modification of lead compound 2, the substitution of a cycloalkyl ring for an N-cyanopy-ridylpiperidine in C4-position was effective for increasing JAK3 inhibitory activity. In addition, modulation of physical properties such as molecular lipophilicity and basicity was important for reducing human ether-a-go-go-related gene (hERG) inhibitory activity. Our optimization study gave compound 31, which exhibited potent JAK3 inhibitory activity as well as weak hERG inhibitory activity. In cellular assay, 31 exhibited potent immunomodulating effect on IL-2-stimulated T cell proliferation. In a pharmacokinetic study, good metabolic stability and oral bioavailability of 31 were achieved in rats, dogs, and monkeys. Further, 31 prolonged graft survival in an in vivo rat heterotopic cardiac transplant model. (C) 2015 Elsevier Ltd. All rights reserved.